Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 12

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 12
---
 we will sell pre-funded warrants to purchase up to an aggregate of 15,667,878 ADSs, representing 235,018,170 of our ordinary shares, and for each ADS and pre-funded warrant purchased in this offering, the investors will receive a warrant to purchase one ADS (a total of warrants to purchase an aggregate of 50,000,000 ADSs, represented by 750,000,000 ordinary shares). This sale and any future sales of a substantial number of ADSs in the public market or the perception that such sales may occur, could cause the market price of our ADSs to decline. There has been and may continue to be significant volatility in the volume and price of the ADSs and ordinary shares. The market price of the ADSs and our ordinary shares has been and may continue to be highly volatile. Factors, including the degree of market acceptance of APHEXDA; the timing, progress and results of current and future preclinical studies and clinical trials and our research and development programs; regulatory matters, concerns about our financial position, operations results, litigation, government regulation, developments or disputes relating to agreements, patents or proprietary rights, any resurgence of the COVID-19 pandemic, and the impact of the security situation in Israel, may have a significant impact on the market volume and price of the ADS and our ordinary shares. Unusual trading volume in our ADSs and our ordinary shares occurs from time to time. There is no public market for warrants or pre-funded warrants being offered by us in this offering. There is no established public trading market for the warrants or pre-funded warrants being offered in this offering, and we do not expect a market to develop. We do not intend to list the warrants or pre-funded warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the warrants and pre-funded warrants will be limited. The warrants and pre-funded warrants are speculative in nature. The warrants and pre-funded warrants do not confer any rights of ordinary share ownership on its holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire ADSs at a fixed price. For example, commencing on the date of issuance, holders of the warrants and pre-funded warrants may exercise their right to acquire the ADSs and pay an exercise price for the warrants and pre-funded warrants, subject to certain adjustments, prior to the four year anniversary of the date of issuance with respect to the warrants, after which date any unexercised warrants will expire